Stock image READING is among the most polluted areas in the UK, with residents exposed to levels above the safe limit recommended by the World Health Organisation (WHO), figures reveal. Health campaigners say toxic air quality in the UK is a national emergency and the government must impose stricter limits on fine particles in the air (PM2.5), which come mainly from the burning of oil, gas and diesel. The calls have been heightened after a coroner, while ruling that air pollution was a cause of the death of a nine-year-old girl in London, said there was no safe level of PM2.5, adding WHO guidelines should be seen as minimum requirements .
Pharmadrug Inc.: PharmaDrug Enters into Employment Agreement with Dr. Paul Van Slyke and Grants Him Options and Promotes Him to Chief Scientific Officer for All of Pharmadrug
PharmaDrug or the
Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into an employment agreement with Dr. Paul Van Slyke and promoted him to Chief Scientific Officer (CSO) for all of PharmaDrug Inc.
As part of the employment agreement, and pursuant to the terms and conditions of the Company s stock option plan, the PharmaDrug Board of Directors has approved the grant of 2,000,000 stock options to Paul Van Slyke. The options expire five years from the date of grant and are exercisable at a price of $0.09 per common share. 500,000 of the options vest immediately and 1,500,000 of the options vest i
PharmaDrug” or the “
Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company’s patented enteric-coated formulation of Cepharanthine (“PD-001”) in a broad panel of human cancers.
We apologize, but this video has failed to load.
Try refreshing your browser. PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer Back to video
Pharmadrug Inc.: PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer
PharmaDrug or the
Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company s patented enteric-coated formulation of Cepharanthine ( PD-001 ) in a broad panel of human cancers. We are focused on advancing the clinical development of our novel Cepharanthine formulation that not only has significant potential for infectious diseases, but also in select rare forms of cancer with high unmet medical needs, said Daniel Cohen, CEO of PharmaDrug
Tokyo Tech and other members of the Super Smart Society (SSS) Promotion Consortium held the 3rd SSS Promotion Forum on March 8, 2021 to introduce the latest technological trends that will contribute t